| 2026-08-04 | 10-Q | 10.4 | Forms of Deferred Settlement RSU Award Grant Notice and Award Agreement pursuant to the Syndax Pharmaceuticals, Inc. 2026 Equity Incentive Plan. |
|---|
| 2026-08-04 | 10-Q | 10.3 | Forms of RSU Award Grant Notice and Award Agreement pursuant to the Syndax Pharmaceuticals, Inc. 2026 Equity Incentive Plan. |
|---|
| 2026-08-04 | 10-Q | 10.2 | Forms of Stock Option Grant Notice and Stock Option Agreement pursuant to the Syndax Pharmaceuticals, Inc. 2026 Equity Incentive Plan. |
|---|
| 2026-06-10 | 8-K | 10.2 | Syndax Pharmaceuticals, Inc. 2026 Employee Stock Purchase Plan |
|---|
| 2026-06-10 | 8-K | 10.1 | Syndax Pharmaceuticals, Inc. 2026 Equity Incentive Plan |
|---|
| 2026-06-04 | 8-K | 10.1 | Form of Subscription Agreement |
|---|
| 2026-02-26 | 10-K | 10.30 | Amendment to Executive Employment by and between the Company and Neil Gallagher, M.D., Ph.D., dated as of February 26, 2024 (incorporated herein by reference to Exhibit 10.30 to the Company's Annual Report on Form 10-K (File No. 001-37708), as filed with the SEC on February 27, 2024). |
|---|
| 2025-05-16 | 8-K | 10.1 | Employment Agreement, dated May 12, 2025, by and between the Company and Dr. Nicholas Botwood |
|---|
| 2025-03-03 | 10-K | 10.43 | Purchase and Sale Agreement by and between the Company and with Royalty Pharma Development Funding, LLC, dated November 4, 2024. |
|---|
| 2025-03-03 | 10-K | 10.28 | Non-employee Director Compensation Policy, as amended, dated as of February 5, 2025. |
|---|
| 2025-03-03 | 10-K | 10.16 | Syndax Pharmaceuticals, Inc. 2023 Inducement Plan, as amended. |
|---|
| 2024-03-18 | 8-K | 10.1 | Employment Agreement, dated March 18, 2024, by and between the Company and Steven Closter |
|---|
| 2024-02-27 | 10-K | 10.31 | Non-employee Director Compensation Policy, as amended, dated as of February 7, 2024. |
|---|
| 2024-02-27 | 10-K | 10.30 | Amendment to Executive Employment by and between the Company and Neil Gallagher, M.D., Ph.D., dated as of February 26, 2024. |
|---|
| 2024-02-27 | 10-K | 10.27 | Amendment to Executive Employment by and between the Company and Keith A. Goldan, dated as of February 26, 2024. |
|---|
| 2024-02-27 | 10-K | 10.25 | Amendment to Executive Employment by and between the Company and Catherine Madigan, M.D., dated as of February 26, 2024. |
|---|
| 2024-02-27 | 10-K | 10.23 | Amendment to Amended and Restated Executive Employment by and between the Company and Luke J. Albrecht, dated as of February 26, 2024. |
|---|
| 2024-02-27 | 10-K | 10.22 | Amended and Restated Executive Employment Agreement by and between the Company and Luke J. Albrecht, dated as of April 27, 2020. |
|---|
| 2024-02-27 | 10-K | 10.20 | Amendment to Amended and Restated Executive Employment by and between the Company and Michael A. Metzger, dated as of February 26, 2024. |
|---|
| 2024-02-27 | 10-K | 10.16 | Syndax Pharmaceuticals, Inc. 2023 Inducement Plan. |
|---|
| 2023-05-08 | 10-Q | 10.2 | Form of Restricted Stock Unit Agreement pursuant to the Syndax Pharmaceuticals, Inc. 2023 Inducement Plan. |
|---|
| 2023-03-30 | 8-K | 10.1 | Employment Agreement, dated March 30, 2023, by and between the Company and Neil Gallagher, M.D., Ph.D. |
|---|
| 2023-02-28 | 10-K | 10.24 | Non-employee Director Compensation Policy, as amended, dated as of February 2, 2023. |
|---|
| 2023-02-08 | 8-K | 10.2 | Form of Option Agreement pursuant to the Syndax Pharmaceuticals, Inc. 2023 Inducement Plan. |
|---|
| 2023-02-08 | 8-K | 10.1 | Syndax Pharmaceuticals, Inc. 2023 Inducement Plan. |
|---|
| 2022-12-05 | 8-K | 10.1 | Employment Agreement, dated December 1, 2022, by and between the Company and Steve Sabus. |
|---|
| 2022-08-08 | 10-Q | 10.1 | Mutual Release and Settlement Agreement by and between the Company and UCB Biopharma SRL, dated as of June 6, 2022. |
|---|
| 2022-06-13 | 8-K | 10.1 | Employment Agreement, dated June 8, 2022, by and between the Company and Keith A. Goldan. |
|---|
| 2022-05-09 | 10-Q | 10.2 | Executive Employment Agreement by and between the Company and Anjali Ganguli, Ph.D., dated as of September 30, 2021. |
|---|
| 2022-05-09 | 10-Q | 10.1 | Executive Employment Agreement by and between the Company and Catherine Madigan, M.D., dated as of March 1, 2022. |
|---|
| 2022-03-01 | 10-K | 10.35 | First Amendment to the Company’s Loan and Security Agreement with the several banks and financial institutions or entities from time-to-time party thereto and Hercules Capital, Inc., in its capacity as administrative agent for itself and the Lender, dated December 22, 2021. |
|---|
| 2022-03-01 | 10-K | 10.19 | Non-employee Director Compensation Policy, as amended, dated as of February 2, 2022. |
|---|
| 2022-03-01 | 10-K | 10.17 | Amended and Restated Executive Employment Agreement by and between the Company and Michael A. Metzger, dated as of February 2, 2022. |
|---|
| 2022-03-01 | 10-K | 10.16 | Amended and Restated Executive Employment Agreement by and between the Company and Briggs W. Morrison, M.D., dated as of February 2, 2022. |
|---|
| 2022-02-03 | 8-K | 10.2 | Amended and Restated Employment Agreement, dated February 2, 2022, by and between the Company and Michael A. Metzger. |
|---|
| 2022-02-03 | 8-K | 10.1 | Amended and Restated Employment Agreement, dated February 2, 2022, by and between the Company and Briggs W. Morrison, M.D. |
|---|
| 2021-11-15 | 10-Q | 10.2 | Stock Purchase Agreement by and between the Company and Incyte Corporation, dated as of September 24, 2021. |
|---|
| 2021-11-15 | 10-Q | 10.1 | Collaboration and License Agreement by and between the Company and Incyte Corporation, dated as of September 24, 2021. |
|---|
| 2021-03-12 | 10-K | 10.14 | Form of Deferred Settlement Stock Unit Agreement under 2015 Omnibus Incentive Plan. |
|---|
| 2020-11-05 | 10-Q | 10.1 | Executive Employment Agreement by and between the Company and Daphne Karydas, dated as of July 6, 2020. |
|---|
| 2020-08-06 | 10-Q | 10.2 | Amendment No. 12 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated May 12, 2020. |
|---|
| 2020-08-06 | 10-Q | 10.1 | Form of Stock Unit Agreement under 2015 Omnibus Incentive Plan. |
|---|
| 2020-05-07 | 10-Q | 10.7 | Amended and Restated Executive Employment Agreement by and between the Company and Richard P. Shea, dated as of April 27, 2020. |
|---|
| 2020-05-07 | 10-Q | 10.6 | Amended and Restated Executive Employment Agreement by and between the Company and Michael L. Meyers, M.D., Ph.D., dated as of April 27, 2020. |
|---|
| 2020-05-07 | 10-Q | 10.5 | Amended and Restated Executive Employment Agreement by and between the Company and Michael A. Metzger, dated as of April 27, 2020. |
|---|
| 2020-05-07 | 10-Q | 10.4 | Amended and Restated Executive Employment Agreement by and between the Company and Briggs W. Morrison, M.D., dated as of April 27, 2020. |
|---|
| 2020-05-07 | 10-Q | 10.3 | Non-employee Director Compensation Policy, as amended, February 12, 2020. |
|---|
| 2020-05-07 | 10-Q | 10.2 | Loan and Security Agreement dated February 7, 2020 between Syndax Pharmaceuticals, Inc. and Hercules Capital, Inc. |
|---|
| 2020-02-04 | 8-K | 10.1 | Purchase Agreement between the Company and the Purchasers, dated January 30, 2020 |
|---|
| 2019-11-07 | 10-Q | 10.2 | Amendment No. 1 to License Agreement by and between the Company and UCB Biopharma Sprl, dated as of July 9, 2019. |
|---|
| 2019-11-07 | 10-Q | 10.1 | Amendment No. 11 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated July 1, 2019. |
|---|
| 2019-05-08 | 10-Q | 10.1 | Amendment No. 1 to License Agreement by and between the Company and Vitae Pharmaceuticals, Inc., dated as of January 25, 2019. |
|---|
| 2019-03-29 | 8-K | 10.2 | Purchase Agreement between the Company and the Purchaser, dated March 28, 2019. |
|---|
| 2019-03-29 | 8-K | 10.1 | Purchase Agreement between the Company and the Purchasers, dated March 26, 2019. |
|---|
| 2019-03-07 | 10-K | 10.35 | Amendment No. 10 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated October 15, 2018. |
|---|
| 2018-08-08 | 10-Q | 10.1 | Amendment #4 to License, Development and Commercialization Agreement by and between the company and Kyowa Hakko Kirin Co., Ltd., dated May 29, 2018. |
|---|
| 2018-06-20 | 8-K | 10.1 | Exchange Agreement between Syndax Pharmaceuticals, Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P. and Biotechnology Value Trading Fund OS, L.P., dated June 18, 2018. |
|---|
| 2018-05-09 | 10-Q | 10.1 | Amendment #3 to License, Development and Commercialization Agreement by and between the company and Kyowa Hakko Kirin Co., Ltd., dated March 27, 2018. |
|---|
| 2018-03-08 | 10-K | 10.47 | License Agreement by and between the Company and Vitae Pharmaceuticals, Inc., dated as of October 13, 2017. |
|---|
| 2018-03-08 | 10-K | 10.34 | Amendment No. 9 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated November 22, 2017. |
|---|
| 2017-10-20 | 8-K | 10.1 | Purchase Agreement, dated October 17, 2017 |
|---|
| 2017-08-10 | 10-Q | 10.2 | Amendment #1 to Clinical Trial Collaboration and Supply Agreement by and between the Company, Merck Sharp & Dohme B.V., and MSD International GmbH, dated as of April 26, 2017. |
|---|
| 2017-08-10 | 10-Q | 10.1 | Executive Employment Agreement by and between the Company and Richard P. Shea, dated as of February 9, 2017. |
|---|
| 2017-05-09 | 10-Q | 10.4 | Side Agreement by and between the Company and UCB Biopharma Sprl, dated March 8, 2017. |
|---|
| 2017-05-09 | 10-Q | 10.3 | Amendment No. 8 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated January 18, 2017. |
|---|
| 2017-05-09 | 10-Q | 10.2 | Amendment #2 to License, Development and Commercialization Agreement by and between the company and Kyowa Hakko Kirin Co., Ltd., dated January 16, 2017. |
|---|
| 2017-05-09 | 10-Q | 10.1 | Amendment No. 7 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated January 9, 2017. |
|---|
| 2016-10-07 | 8-K/A | 10.1 | License Agreement, by and between the Company and UCB Biopharma Sprl, dated July 1, 2016. |
|---|
| 2016-08-15 | 10-Q | 10.4 | Amendment No. 6 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated as of April 25, 2016. |
|---|
| 2016-08-15 | 10-Q | 10.3 | Amendment No. 5 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated as of April 20, 2016. |
|---|
| 2016-08-15 | 10-Q | 10.2 | Amendment No. 4 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated as of April 20, 2016. |
|---|
| 2016-08-15 | 10-Q | 10.1 | Amendment No. 3 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated as of April 20, 2016. |
|---|